Your session is about to expire
← Back to Search
Proteasome Inhibitor
A Study of Real-World Use of Ixazomib Citrate in People With Multiple Myeloma (MM)
N/A
Waitlist Available
Research Sponsored by Takeda
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 6 months
Awards & highlights
No Placebo-Only Group
Summary
In this study, people with MM will be treated with ixazomib citrate according to their clinic's standard practice. The main aim of the study is to check for side effects from ixazomib citrate.
Eligible Conditions
- Multiple Myeloma
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 6 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 6 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Secondary study objectives
Overall Response Rate (ORR)
Progression-free Survival (PFS)
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Participants With MMExperimental Treatment1 Intervention
Participants with MM who are newly prescribed and will start treatment with ixazomib citrate in a real-world clinical practice setting will be observed prospectively for up to 6 years 11 months.
Find a Location
Who is running the clinical trial?
TakedaLead Sponsor
1,240 Previous Clinical Trials
4,147,486 Total Patients Enrolled
50 Trials studying Multiple Myeloma
15,208 Patients Enrolled for Multiple Myeloma
Study DirectorStudy DirectorTakeda
1,290 Previous Clinical Trials
500,527 Total Patients Enrolled
25 Trials studying Multiple Myeloma
4,505 Patients Enrolled for Multiple Myeloma